Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States

Hypertension

Volumn 48, Issue 2, 2006, Pages 213-218

  Stafford, Randall S ^a   Monti, Veronica ^a   Furberg, Curt D ^b   Ma, Jun ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Hypertension, detection and control

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ARTICLE; DRUG CHOICE; DRUG CLASSIFICATION; HEALTH SURVEY; HUMAN; HYPERTENSION; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG UTILIZATION; HUMANS; HYPERTENSION; PHYSICIAN'S PRACTICE PATTERNS; PROPORTIONAL HAZARDS MODELS; TIME; UNITED STATES;

EID: 33748126321     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000229653.73128.b6     Document Type: Article

References (46)

1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
2. Albert MA, Torres J, Glynn RJ, Ridker PM. Perspective on selected issues in cardiovascular disease research with a focus on black Americans. Circulation. 2004;110:e7-e12.
3. Sheats N, Lin Y, Zhao W, Cheek DE, Lackland DT, Egan BM. Prevalence, treatment, and control of hypertension among African Americans and Caucasians at primary care sites for medically under-served patients. Ethn Dis. 2005;15:25-32.
4. Kountz DS. Hypertension in ethnic populations: tailoring treatments. Clin Cornerstone. 2004;6:39-46.
5. Hollar D, Agatston AS, Hennekens CH. Hypertension: trends, risks, drug therapies and clinical challenges in African Americans. Ethn Dis. 2004;14:S2-23-25.
6. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
7. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med. 1996;156:1789-1796.
8. Klungel OH, Heckbert SR, Longstreth WT Jr, Furberg CD, Kaplan RC, Smith NL, Lemaitre RN, Leufkens HG, de Boer A, Psaty BM. Antihypertensive drug therapies and the risk of ischemic stroke. Arch Intern Med. 2001;161:37-43.
9. Wang TJ, Stafford RS. National patterns and predictors of beta-blocker use in patients with coronary artery disease. Arch Intern Med. 1998;158:1901-1906.
10. Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension. 2000;36:600-603.
11. McCracken GH Jr. Clinical practice guidelines for the diagnosis and treatment of respiratory tract infections. Am J Manag Care. 2001;7:S183-S191.
12. Zoorab R, Wormuth C, McCarthy-Larzelere M. Asthma: knowledge and practice patterns of Louisiana family physicians. J La State Med Soc. 2002;154:136-140.
13. Guo JD, Liu GG, Christensen DB, Fu AZ. How well have practices followed guidelines in prescribing antihypertensive drugs: the role of health insurance. Value Health. 2003;6:18-28.
14. Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lesser DS. A physician survey of the effect of drug sample availability on physician's behavior. J Gen Intern Med. 2000;15:478-483.
15. Xu KT, Moloney M, Phillips S. Economics of suboptimal drug use: cost-savings of using JNC recommended medications for management of uncomplicated essential hypertension. Am J Manag Care. 2003;9:529-536.
16. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA. 2004;291:1850-1856.
17. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155:829-837.
18. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
20. Ubel PA, Jepson C, Asch DA. Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians. J Gen Intern Med December. 2003;18:977-983.
21. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA. 1998;279:1813-1816.
22. Furberg CD, Psaty BM, Pahor M, Alderman MH. Clinical implications of recent findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and other studies of hypertension. Ann Intern Med. 2001;135:1074-1078.
23. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;23:2981-2997.
24. Xie F, Petitti DB, Chen W. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization. Am J Hypertens. 2005;18:464-469.
25. Houston MC. ALLHAT debate: diuretics are not preferred, first-line initial therapy for hypertension. Arch Intern Med. 2004;164:570-571.
26. Punzi HA, Punzi CF. Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Trial Study. Curr Hypertens Rep. 2004;6:106-110.
27. Standridge JB. Hypertension and atherosclerosis: clinical implications from the ALLHAT Trial. Curr Atheroscler Rep. 2005;7:132-139.
28. Yusoff K. ALLHAT in perspective: implications to clinical practice and clinical trials. Med J Malaysia. 2005;2:239-245.
29. Aksnes TA, Reims HM, Kjeldsen SE, Mancia G. Antihypertensive treatment and new-onset diabetes mellitus. Curr Hypertens Rep. 2005;7:298-303.
30. Messerli FH, Grossman E. Therapeutic controversies in hypertension. Semin Nephrol. 2005;25:227-235.
31. National Disease and Therapeutic Index Diagnosis Report Documentation. Estimated Sampling Error for Diagnosis Visits, 1990-2004. Plymouth Meeting PA: IMS Health Inc; 2004.
32. Cox DR, Stuart A. Some quick tests for trend and dispersion. Biometrika. 1955;42:80-95.
33. Zou KH, Fielding JR, Silverman SG, Tempany CMC. Hypothesis testing i: proportions. Radiology. 2003;226:609-613.
34. Morgan S, Bassett KL, Wright JM, Yan L. First-line first? Trends in thiazide prescribing for hypertensive seniors. PLoS Med. 2005;2:e80.
35. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
36. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563-1574.
37. Shah SU, Anjum S, Littler WA. Use of diuretics in cardiovascular disease: (2) hypertension. Postgrad Med J. 2004;80:271-276.
38. Arauz PC, Parrott MA, Raskin P, American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care. 2004;27:S65-S67.
39. Wang TJ, Ausiello JC, Stafford RS. Trends in antihypertensive drug advertising, 1985-1996. Circulation. 1999;99:2055-2057.
40. Gu Q, Paulose-Ram R, Dillon C, Burt V. Antihypertensive medication use among US adults with hypertension. Circulation. 2006;113:213-221.
41. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458-1465.
42. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 1997;278:1745-1748.
43. Dexter PR, Perkins S, Overhage JM, Maharry K, Kohler RB, McDonald CJ. A computerized reminder system to increase the use of preventive care for hospitalized patients. N Engl J Med. 2001;345:965-970.
44. Frances CD, Go AS, Dauterman KW, Deosaransingh K, Jung DL, Gettner S, Newman JM, Massie BM, Browner WS. Outcome following acute myocardial infarction: are differences among physician specialties the result of quality of care or case mix? Arch Intern Med. 1999;159:1429-1436.
45. Mehta RH, Das S, Tsai TT, Nolan E, Kearly G, Eagle KA. Quality improvement initiative and its impact on the management of patients with acute myocardial infarction. Arch Intern Med. 2000;160:3057-3062.
46. Sanal S, Aronow WS. Effect of an educational program on the prevalence of use of antiplatelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease. J Gerontol A Biol Sci Med Sci. 2003;58:1046-1048.